The neutralizing epitope ELDKWA on HIV-1 gp41: Genetic variability and antigenicity
- 15 October 2005
- journal article
- Published by Elsevier in Immunology Letters
- Vol. 101 (1) , 81-86
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraintVaccine, 2002
- Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41Journal of Virology, 2001
- Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus ChallengeJournal of Virology, 2001
- Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infectionNature Medicine, 2000
- Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodiesNature Medicine, 2000
- Immunogenic Presentation of a Conserved gp41 Epitope of Human Immunodeficiency Virus Type 1 on Recombinant Surface Antigen of Hepatitis B VirusJournal of General Virology, 1996
- Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5AIDS, 1996
- A Broadly Neutralizing Human Monoclonal Antibody against gp41 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1994
- Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.Proceedings of the National Academy of Sciences, 1994
- Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte ImmortalizationAIDS Research and Human Retroviruses, 1994